Announcements Trials
Browse Landscape

Phase

Phase NA 17Phase 4 3Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 157Neoplasms 115Colorectal Neoplasms 97Breast Neoplasms 90Pancreatic Neoplasms 81Leukemia, Myeloid, Acute 81Recurrence 78Neoplasm Metastasis 78Prostatic Neoplasms 73Melanoma 73Ovarian Neoplasms 72Multiple Myeloma 66Stomach Neoplasms 60Squamous Cell Carcinoma of Head and Neck 55Lung Neoplasms 55Triple Negative Breast Neoplasms 50Glioblastoma 48Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 43Advanced Solid Tumor 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Non-Hodgkin 41Advanced Solid Tumors 37Uterine Cervical Neoplasms 35Small Cell Lung Carcinoma 35Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 29

Interventions

Nerve Growth Factor 1Antibodies 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Cancer Pain × Clear all
NCT07008703 2025-06-06

Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1/2 Recruiting
132 enrolled

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡